PrEP Descovy Oral denied as not medically necessary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for prep descovy oral are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Descovy for PrEP on Medical-Necessity Grounds — and How to Appeal

A medical-necessity denial means UnitedHealthcare determined that the submitted documentation did not demonstrate that Descovy (emtricitabine/tenofovir alafenamide) for PrEP is medically required for this specific patient. In the PrEP context, medical necessity is established by demonstrating that the patient is HIV-negative, has risk factors placing them in a population for whom PrEP is recommended by an accepted clinical guideline, and that Descovy is the clinically appropriate formulation for this individual.

### Why This Is Appealable

Medical-necessity denials for PrEP are frequently overturned when the appeal includes comprehensive clinical documentation that directly addresses each criterion in UHC's coverage policy. The ACA's preventive-services mandate requires coverage of USPSTF Grade A-recommended services — including PrEP for qualifying individuals — without cost-sharing. If your plan is subject to this mandate, a medical-necessity denial may also independently conflict with the preventive-services coverage requirement.

### Your Federal Appeal Rights

• Internal appeal: Under ERISA §503 (employer plans) or ACA §2719 (individual/marketplace plans), you are entitled to a full and fair internal review. File within the deadline on your denial notice.
• External review: After a final internal denial, request IRO review within approximately four months under ACA §2719. The IRO applies accepted clinical standards, not solely UHC's internal criteria.
• Expedited review: If delay would seriously jeopardize your health, request expedited review — typically decided within 72 hours.

### Documentation to Gather

1. Prescriber letter of medical necessity — the most important document. Should confirm: (a) patient is HIV-negative with recent confirmatory testing; (b) patient has documented risk factors consistent with PrEP indication per the applicable guideline organization (e.g., CDC, USPSTF); (c) clinical rationale for Descovy specifically, including any patient-specific factors that make it the appropriate formulation; (d) absence of contraindications to PrEP use. 2. Recent HIV-negative test result — required by the FDA label before initiating PrEP; confirms eligibility and demonstrates clinician due diligence. 3. Documentation of risk factors — chart notes recording the basis for PrEP candidacy consistent with current clinical guidelines. Do not include numeric thresholds; describe the clinical picture. 4. UHC's Coverage Determination Guideline for PrEP — download from UHC's provider portal. Map every criterion to a specific chart fact or prescriber statement. 5. FDA prescribing label for Descovy — confirms the approved indication and any patient-selection considerations relevant to the prescriber's clinical rationale.

### Criteria-Mapping Structure

Build a table with three columns: UHC criterion | Documentation source | Specific chart fact or prescriber statement. Address every criterion listed in the Coverage Determination Guideline, even those that seem straightforward. Reviewers look for gaps; leaving any criterion unaddressed invites a blanket re-denial.

### Common Reasons These Appeals Succeed

Appeals that succeed typically share three features: a detailed prescriber letter (not a form letter), direct criterion-by-criterion mapping, and contemporaneous chart documentation — not reconstructed notes. If the denial letter states a specific missing element, the appeal should open by providing exactly that element.

### Next Step

Obtain UHC's Coverage Determination Guideline for Descovy/PrEP before drafting the appeal. If you cannot locate it, call UHC and request the specific guideline and criteria used in the denial. Every appeal argument should trace back to a criterion in that document.